Clinical trials
STEP-HFpEF: semaglutide and heart failure
Extending the evidence into a difficult-to-treat form of heart failure tied to obesity.
Quick Answer
STEP-HFpEF (NEJM, 2023) tested semaglutide 2.4 mg in adults with obesity-related heart failure with preserved ejection fraction (HFpEF). Semaglutide improved heart-failure symptoms and physical limitations (KCCQ score) and exercise capacity (6-minute walk), alongside weight loss, versus placebo. Compounded semaglutide is not FDA-approved.
Key Facts
- Adults with obesity-related HFpEF
- Improved symptoms and physical function (KCCQ score) vs placebo
- Improved 6-minute walk distance and reduced inflammation (CRP)
- Substantial weight loss accompanied benefits
- Compounded semaglutide is not FDA-approved
HFpEF and obesity
Heart failure with preserved ejection fraction (HFpEF) is common, closely tied to obesity, and historically had few effective therapies. STEP-HFpEF asked whether semaglutide, by treating obesity, could improve this condition.
Design and results
Adults with obesity-related HFpEF received semaglutide 2.4 mg or placebo. Semaglutide produced larger improvements in the KCCQ symptom and physical-limitation score, in the 6-minute walk distance, and in inflammation (CRP), along with substantial weight loss — a consistent pattern of benefit.
Why it matters
For a patient group with limited options, STEP-HFpEF showed an obesity-directed therapy can meaningfully improve symptoms and function. It is part of a broader shift in which GLP-1 therapies are studied for organ-specific outcomes — heart, kidney, liver — not only weight.
Caveats
Heart-failure care is specialist-led and individualized; this is not a treatment recommendation. The branded product was studied. Compounded semaglutide is not FDA-approved.
Frequently asked questions
What did STEP-HFpEF show?
Semaglutide 2.4 mg improved heart-failure symptoms, physical function and exercise capacity in adults with obesity-related HFpEF, alongside weight loss.
Is semaglutide a heart-failure drug?
STEP-HFpEF studied it specifically in obesity-related HFpEF with positive results, but heart-failure treatment is specialist-led and individualized.
References
- Kosiborod MN, et al. Semaglutide in heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- U.S. Food and Drug Administration. Wegovy, Ozempic and Rybelsus (semaglutide) prescribing information. Novo Nordisk.
Citations are for educational reference; this article summarizes published research in plain language and is not medical advice.
Bottom Line
STEP-HFpEF showed semaglutide improved symptoms and function in obesity-related HFpEF — evidence of benefit in a hard-to-treat condition, though care remains specialist-led.